To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID-19 outpatients.
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
CHDR
Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC
